· Venture Capital Tracker · investment-strategies · 2 min read
W Health Ventures Fund II: ~$80M Final Close at ₹700 Cr for Company Creation
W Health Ventures closed Fund II at ₹700 crore (~$80M), above its ₹630 Cr target — a physician-operator company-creation vehicle already launching Everhope Oncology and Everbright Health.
VCT data record
Funding event facts
Source-backed financing and transaction details. Unknown terms remain undisclosed rather than estimated.
W Health Ventures closes Fund II at ₹700 Cr (~$80M)
Healthcare company-creation firm W Health Ventures closed Fund II at ₹700 crore, above its ₹630 crore target, to build 8–10 healthcare companies across India and the US-India corridor.
- Event type
- Fund Close
- Event date
- Sep 8, 2026
- Stage / label
- Fund close
- Amount
- $80M (~₹700 Cr)
- Confidence
- Reported
Company / target: W Health Ventures
Sources: indianstartuptimes.com
W Health Ventures closed Fund II at ₹700 crore (~US$80 million) — above its ₹630 crore target — according to September 8, 2026 coverage (Indian Startup Times). That follows a February 2026 ₹550 crore first close (Economic Times).
Spine: this is a company-creation vehicle, not a classic spray-and-pray seed fund — physicians and operators incubate the thesis before a founding team is hired.
Key facts
| Field | Detail |
|---|---|
| Firm | W Health Ventures (Mumbai, Bengaluru, Delhi, Boston) |
| Fund | Fund II final close ₹700 Cr (~$80M) |
| Prior milestone | First close ₹550 Cr (Feb 2026); target was ₹630 Cr |
| Model | 12–18 months internal de-risking → founding team |
| Pace plan | 8–10 companies / four years; ₹30–50 Cr per incubation; 2–3/year |
| Fund II launches cited | Everhope Oncology (with Narayana Health); Everbright Health (US TRD clinics) |
| Firm claim | Portfolio companies reached 25M patients to date |
Who this capital serves
Patients/providers: new category companies in oncology, psychiatry, chronic care, and related gaps where WHV believes first-mover coordinated care beats incremental clinic SaaS.
Founding CEOs: operators plugged into a pre-diligence thesis rather than a blank-sheet seed.
LPs: healthcare specialists who want India + US-India corridor exposure with operational involvement baked in.
Why now
- India healthcare demand is scaling faster than coordinated specialty capacity (oncology, obesity, mental health).
- Cross-border US-India psychiatry/oncology plays need patient capital that can wait through incubation.
- Completing above target after a February first close suggests LP demand for builder funds outpaced the original ₹630 Cr ask.
What is not proven
- LP roster and management fees were not detailed in the IST piece.
- “25 million patients” is a firm claim across the portfolio, not Fund II alone.
- FX on ~$80M is illustrative (~₹87.5/$); lead with ₹700 Cr as the disclosed close figure.
Implication
WHV’s scoreboard is companies launched and clinical outcomes, not deal count. Watch whether Everhope and Everbright raise external growth capital on schedule — that is how Fund I was validated.
Sources
- 2026-vc-news
- fund-news
- venture-capital
- +3 more
Follow Venture Capital Tracker in Google
Add VCT as a preferred source to make our venture-capital coverage easier to find in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
